بدائل البحث:
significant decrease » significant increase (توسيع البحث), significantly increased (توسيع البحث)
increase » increased (توسيع البحث)
significant decrease » significant increase (توسيع البحث), significantly increased (توسيع البحث)
increase » increased (توسيع البحث)
-
19361
Table 4_Global, regional, and national temporal trends in prevalence, deaths and disability-adjusted life years for chronic pulmonary disease, 1990–2021: an age-period-cohort analy...
منشور في 2025"…However, age-standardized deaths and DALYs significantly decreased across all five SDI regions. …"
-
19362
Data Sheet 3_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
منشور في 2025"…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …"
-
19363
Data Sheet 1_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
منشور في 2025"…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …"
-
19364
Data Sheet 8_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
منشور في 2025"…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …"
-
19365
Supplementary file 1_Global, regional, and national temporal trends in prevalence, deaths and disability-adjusted life years for chronic pulmonary disease, 1990–2021: an age-period...
منشور في 2025"…However, age-standardized deaths and DALYs significantly decreased across all five SDI regions. …"
-
19366
Data Sheet 9_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
منشور في 2025"…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …"
-
19367
Table 2_Global, regional, and national temporal trends in prevalence, deaths and disability-adjusted life years for chronic pulmonary disease, 1990–2021: an age-period-cohort analy...
منشور في 2025"…However, age-standardized deaths and DALYs significantly decreased across all five SDI regions. …"
-
19368
Table 1_Global, regional, and national temporal trends in prevalence, deaths and disability-adjusted life years for chronic pulmonary disease, 1990–2021: an age-period-cohort analy...
منشور في 2025"…However, age-standardized deaths and DALYs significantly decreased across all five SDI regions. …"
-
19369
Data Sheet 4_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
منشور في 2025"…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …"
-
19370
Rht1 functions in cell cycle progression and modulates fluconazole susceptibility.
منشور في 2025"…Log rank (Mantel-Cox) test assessed significant difference between wild type and <i><i>rht1</i></i>Δ/Δ. …"
-
19371
Data Sheet 7_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
منشور في 2025"…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …"
-
19372
Table 3_Global, regional, and national temporal trends in prevalence, deaths and disability-adjusted life years for chronic pulmonary disease, 1990–2021: an age-period-cohort analy...
منشور في 2025"…However, age-standardized deaths and DALYs significantly decreased across all five SDI regions. …"
-
19373
Data Sheet 11_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti...
منشور في 2025"…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …"
-
19374
Data Sheet 5_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
منشور في 2025"…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …"
-
19375
Genetic interaction between <i>Zrf1</i> and RISC components regulates ISC proliferation during midgut damage.
منشور في 2025"…</b> Box plots show median, quartiles, and range. Statistical significance determined by Student’s t-test; ns = not significant, **p < 0.01, ****p < 0.0001.…"
-
19376
Table 1_Expression and diagnostic values of ferroptosis-related genes in coronavirus-associated viral sepsis.xlsx
منشور في 2025"…Functional enrichment analyses using GO and KEGG revealed significant enrichment in signaling pathways related to ferroptosis, oxidative stress, and HIF-1. …"
-
19377
Table 1_Vitamin D3 promotes white fat beige through IL-27/P38MAPK/PGC-1α pathway.docx
منشور في 2025"…After VD<sub>3</sub> intervention, TC, TG, and the number of LDs were significantly reduced in both HFD rats and 3T3-L1 cells, and serum IL-6 and MCP-1 in HFD rats were decreased. …"
-
19378
Data Sheet 2_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic...
منشور في 2025"…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …"
-
19379
Data Sheet 10_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti...
منشور في 2025"…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …"
-
19380
Data Sheet 12_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti...
منشور في 2025"…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …"